Clarithromycin-associated	clarithromycin-associated	O	O	O	O
visual	visual	O	DISEASE	OTHERS	I
hallucinations	hallucinations	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
chronic	chronic	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
on	on	O	O	O	O
continuous	continuous	O	O	O	O
ambulatory	ambulatory	O	O	O	O
peritoneal	peritoneal	O	O	O	O
dialysis	dialysis	O	O	O	O
.	.	O	O	O	O

Visual	visual	O	DISEASE	OTHERS	I
hallucinations	hallucinations	O	DISEASE	OTHERS	I
are	are	O	O	O	O
a	a	O	O	O	O
rare	rare	O	O	O	O
event	event	O	O	O	O
in	in	O	O	O	O
chronic	chronic	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
and	and	O	O	O	O
not	not	O	O	O	O
related	related	O	O	O	O
to	to	O	O	O	O
uremia	uremia	O	O	OTHERS	I
per	per	O	O	O	O
se	se	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Unreported	unreported	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
literature	literature	O	O	O	O
is	is	O	O	O	O
visual	visual	O	DISEASE	OTHERS	I
hallucinations	hallucinations	O	DISEASE	OTHERS	I
occurring	occurring	O	O	O	O
in	in	O	O	O	O
association	association	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
new	new	O	O	O	O
macrolide	macrolide	O	O	OTHERS	I
antibiotic	antibiotic	O	O	O	O
,	,	O	O	O	O
clarithromycin	clarithromycin	O	O	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
describe	describe	O	O	O	O
such	such	O	O	O	O
a	a	O	O	O	O
case	case	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
end-stage	end-stage	O	O	O	O
renal	renal	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
(	(	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
)	)	O	O	O	O
maintained	maintained	O	O	O	O
on	on	O	O	O	O
continuous	continuous	O	O	O	O
ambulatory	ambulatory	O	O	O	O
peritoneal	peritoneal	O	O	O	O
dialysis	dialysis	O	O	O	O
(	(	O	O	O	O
CAPD	capd	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
relatively	relatively	O	O	O	O
high	high	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
clarithromycin	clarithromycin	O	O	OTHERS	I
in	in	O	O	O	O
face	face	O	O	O	O
of	of	O	O	O	O
chronic	chronic	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
functionally	functionally	O	O	O	O
anephric	anephric	O	O	O	O
patient	patient	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
underlying	underlying	O	O	O	O
aluminum	aluminum	O	O	OTHERS	I
intoxication	intoxication	O	O	O	O
,	,	O	O	O	O
may	may	O	O	O	O
have	have	O	O	O	O
facilitated	facilitated	O	O	O	O
the	the	O	O	O	O
appearance	appearance	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
neurotoxic	neurotoxic	O	DISEASE	OTHERS	I
side	side	O	O	O	O
effect	effect	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
is	is	O	O	O	O
important	important	O	O	O	O
to	to	O	O	O	O
understand	understand	O	O	O	O
the	the	O	O	O	O
pharmacokinetics	pharmacokinetics	O	O	O	O
of	of	O	O	O	O
medications	medications	O	O	O	O
in	in	O	O	O	O
face	face	O	O	O	O
of	of	O	O	O	O
chronic	chronic	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
possibility	possibility	O	O	O	O
of	of	O	O	O	O
drug	drug	O	O	O	O
interactions	interactions	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
how	how	O	O	O	O
these	these	O	O	O	O
factors	factors	O	O	O	O
should	should	O	O	O	O
help	help	O	O	O	O
guide	guide	O	O	O	O
medication	medication	O	O	O	O
therapy	therapy	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
patient	patient	O	O	O	O
.	.	O	O	O	O

